Dexmedetomidine-flurbiprofen axetil-based opioid-free analgesia improves postoperative sleep quality and attenuates melatonin suppression after thyroidectomy
In a randomized controlled trial of 96 patients undergoing thyroidectomy, an opioid-free PCIA regimen (dexmedetomidine, flurbiprofen axetil, ondansetron) significantly improved sleep quality (RCSQ scores, P<0.001) and preserved nocturnal melatonin secretion (urinary 6-SMT, P<0.001) compared to opioid-based PCIA (sufentanil, ondansetron). The opioid-free group also showed shorter sleep latency, fewer nocturnal awakenings, longer total sleep time, lower anxiety, and reduced opioid-related adverse events.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Dexmedetomidine-flurbiprofen axetil-based opioid-free analgesia improves postoperative sleep quality and attenuates melatonin suppression after thyroidectomy The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Dexmedetomidine-flurbiprofen axetil-based opioid-free analgesia improves postoperative sleep quality and attenuates melatonin suppression after thyroidectomy
This conclusion is most relevant to: 96 patients undergoing thyroidectomy.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Dexmedetomidine-flurbiprofen axetil-based opioid-free analgesia attenuates postoperative melatonin suppression and improves sleep quality after thyroidectomy: a randomized controlled trial. (Frontiers in pharmacology, 2026) —
How It Works
The proposed biological pathway:
- ▸Dexmedetomidine provides sedation and analgesia without opioid receptor activation
- ▸Flurbiprofen axetil reduces inflammation and pain via COX inhibition
- ▸Avoidance of opioids prevents suppression of nocturnal melatonin secretion
- ▸Improved melatonin secretion leads to better sleep quality and reduced anxiety
Who Might Benefit
Evidence fit by population:
- ▸96 patients undergoing thyroidectomy
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Single-center study with relatively small sample size (n=96)
- ▸Short follow-up limited to postoperative days 1 and 2, not assessing long-term sleep outcomes
Frequently Asked Questions
What is the primary benefit of opioid-free analgesia for sleep after thyroidectomy?▼
The opioid-free regimen based on dexmedetomidine and flurbiprofen axetil significantly improves sleep quality and preserves nocturnal melatonin secretion compared to opioid-based analgesia.
Does the opioid-free regimen provide adequate pain control?▼
Yes, postoperative pain intensity and sedation levels were comparable between the opioid-free and opioid groups at all measured time points.
What adverse events are reduced with opioid-free analgesia?▼
The incidences of nausea, vomiting, and pruritus were significantly reduced in the opioid-free group.
How was sleep quality measured in this study?▼
Sleep quality was assessed using the Richards-Campbell Sleep Questionnaire (RCSQ) and detailed sleep parameters including sleep latency, nocturnal awakenings, and total sleep time.
References
- 1.Guo R, Luo X, Chen L, Rao PG, Wang LF, Lei XH, Dai GY, Fang H. “Dexmedetomidine-flurbiprofen axetil-based opioid-free analgesia attenuates postoperative melatonin suppression and improves sleep quality after thyroidectomy: a randomized controlled trial..” Frontiers in pharmacology, 2026. PMID: 42465992 DOI: 10.3389/fphar.2026.1839440